证券代码：002287 证券简称：奇正藏药 公告编号：2025-098 西藏奇正藏药股份有限公司 第六届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、西藏奇正藏药股份有限公司（以下简称"公司"）第六届董事会第十五次 会议于 2025 年 11 月 10 日以电子通信形式召开； 2、会议通知于 2025 年 11 月 5 日以电子邮件、电话、信息等方式发出； 3、会议应出席董事 7 人，实际出席会议董事 7 人，其中独立董事 3 名，公 司监事及高级管理人员列席了会议； 4、会议由公司董事长刘凯列先生召集并主持； 5、本次会议的出席人数、召集召开程序、议事内容符合《公司法》和《公 司章程》的相关规定。 二、董事会会议审议情况 1、审议通过了《关于取消监事会及修订<公司章程>的议案》； 为进一步完善公司治理结构，根据《中华人民共和国公司法》、《关于新< 公司法>配套制度规则实施相关过渡期安排》、《上市公司章程指引》、《深圳 证券交易所股票上市规则》等有关法律法规及规范性文件的规定，结合公司实际 情况，公司拟 ...

每经头条（nbdtoutiao）——进博会"爆品"来袭！德国"天价"扳手引围观，阿根廷牛儿为中国"贴膘"，卢 旺达咖啡豆火出圈…… （记者 王瀚黎） 每经AI快讯，奇正藏药（SZ 002287，收盘价：25.51元）11月10日晚间发布公告称，公司第六届第十五 次董事会会议于2025年11月10日以电子通信形式召开。会议审议了《关于修订 <董事会审计委员会工作 细则> 的议案》等文件。 2025年1至6月份，奇正藏药的营业收入构成为：医药业占比99.39%，其他占比0.61%。 截至发稿，奇正藏药市值为146亿元。 ...

因公司实施 2025 年半年度权益分派，公司回购股份价格上限自 2025 年 9 月 22 日起由不超过 31.27 元/股调整为不超过 31.05 元/股。详见 2025 年 9 月 13 日刊登在《证券时报》、巨潮资讯网（http://www.cninfo.com.cn）上的《关 于 2025 年半年度权益分派实施后调整回购股份价格上限的公告》（公告编号： 2025-092）。 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引 第 9 号——回购股份》（以下简称"《回购指引》"）等法律法规、规范性文件 的有关规定，回购期间，公司应在每个月的前三个交易日内披露截至上月末的回 购进展情况。现将公司截至上月末的回购股份的进展情况公告如下： 一、回购股份的进展情况 证券代码：002287 证券简称：奇正藏药 公告编号：2025-097 西藏奇正藏药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 西藏奇正藏药股份有限公司（以下简称"公司"）于 2025 年 2 月 27 日召开 第六届董事会第九次会议，审议 ...

Core Insights - The Tibet Qizheng Tibetan Medicine Co., Ltd. won the "Outstanding Award" at the Ram Charan Management Practice Award for its case study on sustainable business models and governance practices [1] Sustainable Business Model - The company emphasizes the importance of biodiversity and environmental protection in the Qinghai-Tibet Plateau, having completed resource surveys for over 120 Tibetan medicinal materials and established standards for over 60 local varieties [2] - Qizheng has developed a functional base system covering wild nurturing, semi-wild planting, artificial breeding of rare and endangered medicinal materials, and industrialized planting, with a total area exceeding 500,000 acres [2] - The company respects the rights of indigenous people and has established a benefit-sharing mechanism, promoting low-carbon concepts and high-standard green production through smart factories [2] - Qizheng's production process is inherently low-pollution and generates less waste, and the company has implemented an environmental management system certified by national standards [2] - The Qizheng Foundation supports Tibetan medicine culture through various projects, creating a mutually beneficial ecosystem with stakeholders including patients, employees, and suppliers [2] Sustainable Governance Practices - Since 2012, the company has been systematically building a sustainable development management system, with plans to upgrade its ESG framework by 2025 [3] - The strategic "Five Trees" model integrates disease, health, technology, products, and brand into a comprehensive layout, ensuring seamless connection between strategy and operational plans [3] - The company enforces a "one-vote veto" system in product development, prohibiting the market introduction of any product relying on endangered or scarce resources without completed resource planning [3] - Qizheng is advancing organizational youthfulness and establishing a modern enterprise management system to attract and cultivate professional talent [3] - The founder of Qizheng received the inaugural Peter Drucker China Management Award in 2019 for promoting sustainable development principles in Tibetan medicine [3]

Core Insights - The Tibet Qizheng Tibetan Medicine Co., Ltd. won the "Outstanding Award" at the Ram Charan Management Practice Award for its case study on sustainable business models and governance practices [1] Sustainable Business Model - The company emphasizes the importance of biodiversity and environmental protection in the Qinghai-Tibet Plateau, having completed resource surveys for over 120 Tibetan medicinal materials and established standards for over 60 local varieties [2] - Qizheng has developed a functional base system covering wild nurturing, semi-wild planting, artificial breeding of rare and endangered medicinal materials, and industrialized planting, with a total area exceeding 500,000 acres [2] - The company respects the rights of indigenous people and has established a benefit-sharing mechanism, promoting low-carbon concepts and high-standard green production through smart factories [2] - Qizheng's production process is inherently low-pollution and generates less waste compared to chemical drugs, and it has implemented an environmental management system certified by ISO14001 and received a B-level certificate for environmental standardization [2] - The company promotes Tibetan medicine culture through initiatives like the Qizheng Foundation and the "Hundred Clinics Plan," fostering a mutually beneficial ecosystem with stakeholders [2] Sustainable Governance Practices - Since 2012, Qizheng has been systematically constructing a sustainable development management system, with plans to upgrade its ESG framework by 2025 [3] - The company has established a "Strategic Five Trees" model to create a comprehensive layout linking disease, health, technology, products, and brand, ensuring seamless integration of strategy and operational plans [3] - Qizheng enforces a "one-vote veto" system in product development, prohibiting the market introduction of any strategic products relying on endangered or scarce resources without completed resource planning [3] - The company is advancing organizational youthfulness and building a management foundation centered on modern corporate systems, ensuring that a professional team drives corporate development [3] - The founder of Qizheng, Lei Jufang, received the first Peter Drucker Management Award in China for his sustainable development practices in Tibetan medicine [3]

Core Insights - The Tibet Qizheng Tibetan Medicine Co., Ltd. won the "Outstanding Award" at the Ram Charan Management Practice Award for its case study on sustainable business models and governance practices [1] Sustainable Business Model - The company emphasizes the importance of biodiversity and natural environment protection in the Qinghai-Tibet Plateau, having completed resource surveys for over 120 Tibetan medicinal materials and established standards for over 60 local varieties [2] - Qizheng has developed a functional base system covering wild nurturing, semi-wild planting, artificial breeding of rare and endangered medicinal materials, and industrialized planting, with a total area exceeding 500,000 acres [2] - The company respects the rights of indigenous people and has established a benefit-sharing mechanism, promoting low-carbon concepts and high-standard green production through smart factories [2] - Qizheng's production process is characterized by low pollution and minimal waste, and it has implemented an environmental management system certified by national standards [2] - The company promotes Tibetan medicine culture through projects like the Qizheng Foundation and the "Hundred Clinics Plan," creating a mutually beneficial ecosystem with stakeholders [2] Sustainable Governance Practices - Since 2012, the company has been systematically building a sustainable development management system, with plans to upgrade its ESG framework by 2025 [3] - Qizheng has established a "Strategic Five Trees" model to link strategy and operational plans seamlessly, covering the entire chain from disease to health, technology, products, and branding [3] - The company enforces a "one-vote veto" system in product development, prohibiting the market introduction of any strategic products relying on endangered or scarce resources without completed resource planning [3] - Qizheng is focused on organizational succession and talent cultivation, promoting a younger workforce and establishing a management foundation centered on modern corporate systems [3] - The founder of Qizheng, Lei Jufang, received the first Peter Drucker Management Award in China for his sustainable development practices in Tibetan medicine [3]

Core Insights - The Ram Charan Management Practice Award recognized Qizheng Tibetan Medicine for its outstanding case study on sustainable business models and governance practices [2][4] - The award highlights Qizheng's innovative approaches in the sustainable development of traditional Chinese medicine and ethnic medicine [2] Company Overview - Qizheng Tibetan Medicine has prioritized biodiversity and environmental protection in the Qinghai-Tibet Plateau [2] - The company has conducted resource surveys on over 120 Tibetan medicinal materials and established standards for more than 60 local varieties [2] - Qizheng has implemented research on cultivation techniques for 58 medicinal materials, creating a functional base system covering over 500,000 acres [2] Environmental Practices - The company actively promotes low-carbon principles and high-standard green production [2] - Qizheng has built an intelligent factory and established an environmental management system covering all production stages [2] Cultural and Educational Initiatives - Through the Qizheng Foundation, the company promotes Tibetan medicine culture via grassroots education and clinic initiatives [3] - Qizheng aims to create a symbiotic business ecosystem with stakeholders [3] Strategic Planning - The company has developed a "Strategic Five Trees" model, linking disease, health, technology, products, and brand for seamless strategic and operational integration [3] - Qizheng enforces a "one-vote veto" system in product development, ensuring that any marketable variety relying on endangered resources is not advanced without proper resource planning [3] Organizational Development - Qizheng is advancing organizational youthfulness and establishing a modern management system to attract and cultivate professional talent [3]

Core Insights - The company, Qizheng Tibetan Medicine, won the "Outstanding Award" at the Ram Charan Management Practice Award for its case study on sustainable business models and governance practices [1][3] - The award highlights the company's innovative approach to sustainable business practices in the traditional Chinese medicine and ethnic medicine sectors [1] Group 1: Sustainable Practices - Qizheng Tibetan Medicine emphasizes biodiversity and environmental protection, having completed resource surveys for over 120 Tibetan medicinal materials and established standards for more than 60 local varieties [1] - The company has conducted research on cultivation techniques for 58 types of Tibetan medicinal materials and developed a functional base system covering over 500,000 acres [1] - The company actively promotes low-carbon principles and high-standard green production, creating smart factories and implementing an environmental management system across all production stages [1] Group 2: Cultural and Strategic Initiatives - Through the Qizheng Foundation, the company promotes Tibetan medicine culture via projects like folk Tibetan medicine education and a clinic initiative, fostering a symbiotic business ecosystem [2] - The company has developed a "Strategic Five Trees" model, linking disease, health, technology, products, and brand to ensure seamless integration of strategy and operational plans [2] - In product development, the company enforces a "one-vote veto" system, prohibiting the market introduction of any potentially viable products that rely on endangered or scarce resources without completed resource planning [2] Group 3: Management and Recognition - The recent award serves as authoritative recognition of the company's sustainable business model and management practices [3] - In 2019, the founder of Qizheng Tibetan Medicine received the inaugural Peter Drucker Management Award in China for her commitment to sustainable development and social responsibility in the Tibetan medicine sector [3]

Core Points - The company has officially announced the transformation of its "Board Strategic Investment Committee" into the "Board Strategic Investment and ESG Committee," integrating ESG principles into its core decision-making framework [1] - This move aligns with recent regulatory requirements and reflects the growing importance of ESG in the pharmaceutical industry, particularly in relation to public health and capital market recognition [1][2] Group 1: Committee Adjustments - The name change emphasizes the equal importance of ESG alongside strategic investment, moving away from the previous perception of ESG as a secondary concern [2] - The committee's responsibilities have expanded to include five core ESG functions, such as developing top-level ESG planning and assessing ESG impacts on significant company matters [2] - The composition and terms of the committee members remain unchanged to ensure continuity in strategic investment decisions while facilitating the quick implementation of ESG responsibilities [2] Group 2: Industry Leadership - The restructuring represents a systematic leap for the company, building on its years of exemplary ESG practices and providing a replicable model for the Tibetan medicine and ethnic medicine sectors [3] - The company has achieved an ESG A-level rating and has received multiple awards for its ESG efforts, including recognition for its social responsibility and sustainable development initiatives [3] - As of the end of 2024, the company's public welfare foundation has invested a total of 169.2 million yuan in charitable activities, demonstrating a long-term commitment to sustainability and transparency in ESG reporting [3]

Core Viewpoint - Qizheng Tibetan Medicine (002287.SZ) reported a revenue of 1.523 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 3.48% [1] - The net profit attributable to shareholders of the listed company reached 424 million yuan, marking a year-on-year increase of 7.66% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 282 million yuan, with a year-on-year growth of 4.21% [1] Financial Performance - Revenue for the first three quarters: 1.523 billion yuan, up 3.48% year-on-year [1] - Net profit attributable to shareholders: 424 million yuan, up 7.66% year-on-year [1] - Net profit after deducting non-recurring gains and losses: 282 million yuan, up 4.21% year-on-year [1]